A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis

I. Gjorup; O. Roikjaer; B. Andersen; F. Burcharth; C. Hovendal; S. A. Pedersen; P. Christiansen; P. Wara; J. C. Andersen; I. Balslev; J. Jepsen; M. Rokkjaer

A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis

I. Gjorup^*, O. Roikjaer, B. Andersen, F. Burcharth, C. Hovendal, S. A. Pedersen, P. Christiansen, P. Wara, J. C. Andersen, I. Balslev, J. Jepsen, M. Rokkjaer

^*Corresponding author for this work

44 Citations (Scopus)

Abstract

To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.

Original language	English
Journal	Surgery Gynecology and Obstetrics
Volume	175
Issue number	5
Pages (from-to)	397-400
Number of pages	4
ISSN	0039-6087
Publication status	Published - 1 Jan 1992

Cite this

@article{06a6faf652d14275a26b2d2c85ce6dbd,

title = "A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis",

abstract = "To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.",

author = "I. Gjorup and O. Roikjaer and B. Andersen and F. Burcharth and C. Hovendal and Pedersen, {S. A.} and P. Christiansen and P. Wara and Andersen, {J. C.} and I. Balslev and J. Jepsen and M. Rokkjaer",

year = "1992",

month = jan,

day = "1",

language = "English",

volume = "175",

pages = "397--400",

journal = "Surgery Gynecology and Obstetrics",

issn = "0039-6087",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis

AU - Gjorup, I.

AU - Roikjaer, O.

AU - Andersen, B.

AU - Burcharth, F.

AU - Hovendal, C.

AU - Pedersen, S. A.

AU - Christiansen, P.

AU - Wara, P.

AU - Andersen, J. C.

AU - Balslev, I.

AU - Jepsen, J.

AU - Rokkjaer, M.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.

AB - To evaluate the effect of somatostatin in the treatment of acute pancreatitis, 63 patients were randomly allocated to continuous intravenous infusion for three days of 250 micrograms of somatostatin (Dura Scan, Odense, Denmark) per hour (n=33), or placebo (n=30). Patients with a first attack of pancreatitis, serum amylase level of more than 450 units per liter and symptoms for less than 24 hours were eligible for participation in the study. Apart from a slightly significant faster decrease in serum amylase concentrations, we were unable to demonstrate any significant benefit from somatostatin with regard to paraclinical values and clinical course.

UR - http://www.scopus.com/inward/record.url?scp=0026498680&partnerID=8YFLogxK

M3 - Journal article

C2 - 1279821

AN - SCOPUS:0026498680

SN - 0039-6087

VL - 175

SP - 397

EP - 400

JO - Surgery Gynecology and Obstetrics

JF - Surgery Gynecology and Obstetrics

IS - 5

ER -

A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis

Abstract

Other files and links

Fingerprint

Cite this